Latest Breaking News On - Bempedoic acid - Page 1 : comparemela.com

Transcripts For KNTV NBC Nightly News With Lester Holt 20240706

went to the hospital what you need to know. a tanker truck explodes on the highway in maryland. nearby homes up in flames look at this! look at this the new mug shot of alex mur dau, head shaved and the new interview with a juror and one piece of evidence he says convinced him he was guilty. reports of new gas attacks targeting girls schools across iran girls collapsing, hundreds hospitalized. the major medical study on a statin alternative to lower cholesterol. how it could help millions. and remembering tom sizemore, the actor known for his tough-guy roles and hard-lived life has died announcer: this is nbc nightly news with jose diaz-balart good evening millions of americans on both coasts are dealing with major snowfall right now this is the scene in northern california where they re expected to see as much as five feet of snow in the southern part of that state, residents are still trapped in their homes, many running low on food and supplies after gettin

Nightly newsSatellite viewSunday morningSnow levelsA millionHelp usSouthern californiaSnow makerAir turbulenceTanker truckGirls schoolsGas attacksMug shotAlex mur dauTom sizemoreGirls collapsing

Daiichi Sankyo Europe GmbH: First-in-class cholesterol-lowering treatment NILEMDO? and its combination with ezetimibe, NUSTENDI?, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk

NILEMDO? (bempedoic acid), a first-in-class, oral treatment and NUSTENDI? (bempedoic acid ezetimibe fixed-dose combination) receive label update approval from the European Commission as treatments

United kingdomDaiichi sankyo europe gmbSheldon koenigAlberico catapanoGillian dsouzaDaiichi sankyoOliver appelhansDaiichi sankyo europeUniversity of milanEuropean atherosclerosis societyEuropean society of cardiologyEuropean medicines agencyEuropean commissionHead of europe specialty divisionEsperion therapeutics incEuropean commissionas

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U S ) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U S ), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U S ) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U S ), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Tiffany aldrichWolfgang schiessl europeDaiichi sankyo europeOliver appelhansDaiichi sankyo europe gmbAlberico catapanoDaiichi sankyoSheldon koenigHead of europe specialty divisionExchange commissionEuropean commissionEsperion therapeutics incUniversity of milanOral treatmentEzetimibe fixed dose combinationReceive label update approval

CLEAR Outcomes Analysis Finds Bempedoic Acid Reduces Total Cardiovascular Events by 20%

In the CLEAR Outcomes trial, bempedoic acid was associated with a 20% reduction in relative risk for total cardiovascular events, with further analysis shining light on the effects of specific types of events.

Steve nissenCampbellp bempedoicAmerican college of cardiologyAmerican collegeCleveland clinicInterquartile rangeBempedoic acidTotal cardiovascular eventsPrespecified analysisRandomized clinical

Clinical Trial Results on Novel Nonstatins Agents

Expert cardiologists discuss the recent clinical trials results of the CLEAR-OUTCOMES trial and thee sub analysis on the inflammatory marker hcCRP.

Bempedoic acidStatin intolerantClear outcomesUric acidEndo renalLiver disease